University of Chicago

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Chicago sits in the top decile of US sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count).

796 total trials 158 currently recruiting 451 completed early-phase tilt top decile by trial count

University of Chicago: 796 sponsored US clinical trials, 158 recruiting.

University of Chicago sponsors 796 registered US clinical trials on ClinicalTrials.gov, 158 of them currently recruiting, and 451 completed. 67 of these trials are in Phase 3-4 (later-stage) and 293 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 11 trials.

Top-decile sponsor footprint

University of Chicago ranks in the top decile of sponsors by registered trial count (#41 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 40/100

451 of 562 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

796 total, page 8 of 16

COMPLETED Phase 1

Mood Effects of Serotonin Agonists

NCT03790358
COMPLETED NA

Communication Bridge 2

NCT03371706
COMPLETED Phase 4

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

NCT02859142
TERMINATED Phase 2

Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy

NCT03463161
COMPLETED Phase 2

Tolcapone in Obsessive Compulsive Disorder

NCT03348930
COMPLETED Phase 1

Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer

NCT03431948
COMPLETED NA

Tragus Stimulation to Prevent Atrial Fibrillation After Cardiac Surgery

NCT03392649
COMPLETED

Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization

NCT03305874
COMPLETED

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

NCT03344094
TERMINATED Phase 2

Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer

NCT03225547
COMPLETED NA

Prognosis--A Game-Based Intervention to Improve STEM Skills

NCT03416218
COMPLETED Phase 4

A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia

NCT03360903
COMPLETED NA

Cardiogenic Shock Intravascular Cooling Trial

NCT03141255
COMPLETED NA

An Emotion-Focused Intervention for Glycemic Control in T2D

NCT03553680
COMPLETED NA

Project WERK (Wellness Encouragement Respect Kinship)

NCT03148171
COMPLETED NA

Chicago Community Health Study

NCT04460417
COMPLETED NA

The Impact of a School-Based, Trauma-Informed CBT Intervention for Young Women

NCT03376633
TERMINATED NA

Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling

NCT03281928
TERMINATED NA

Feasibility of At-Home Handheld Spirometry

NCT03284203
COMPLETED

Implants on Mobile Health Unit

NCT03347539
TERMINATED Phase 2

Afatinib in Advanced Refractory Urothelial Cancer

NCT02122172
TERMINATED Phase 1

Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer

NCT03203304
COMPLETED NA

Diet and Sleep Monitoring

NCT03257137
COMPLETED

Parkinson's Disease in African American and Caucasian Patients

NCT03279445
COMPLETED Phase 2

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

NCT02969837
COMPLETED Phase 2

Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

NCT03107182
TERMINATED

Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening

NCT04877912
TERMINATED Phase 2

Effects of Pregnenolone on Perceived Social Isolation

NCT02826577
COMPLETED NA

Newborn Implementation

NCT03366831
TERMINATED Phase 1

Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies

NCT02985554
COMPLETED Early Phase 1

Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation

NCT02981914
COMPLETED NA

TMP-Visitas al Hogar

NCT03076268
COMPLETED Early Phase 1

Developing a Mobile Method to Measure THC-induced Impairment

NCT03804840
COMPLETED Early Phase 1

Effects of THC on Emotional Memory Retrieval

NCT03471585
TERMINATED NA

Utility of Diffusion-weighted MR Imaging

NCT03078868
COMPLETED NA

Identifying At-Risk Patients and Predicting Deterioration of In-Patients Using Continuous Heart Rate, Respiratory Rate, and Movement Monitoring

NCT03010774
COMPLETED Phase 1

Differential Responses to Drugs and Sweet Tastes

NCT03810703
COMPLETED Phase 2

A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients

NCT03030989
COMPLETED Phase 3

Metoprolol to Reduce Perioperative Myocardial Injury

NCT03138603
COMPLETED NA

In-School Evaluation of Bystander: A Game-Based Intervention for Sexual Violence Prevention

NCT02919098
TERMINATED NA

Effects of Flibanserin on the Pre- and Post-menopausal Female Brain

NCT02770768
COMPLETED Phase 4

A Study to Determine if Caffeine Accelerates Emergence From Anesthesia

NCT02567968
TERMINATED Phase 1

Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

NCT02782182
COMPLETED Phase 1

Effect of Stimulant Drugs on Social Perception

NCT03790618
COMPLETED Phase 2

Vortioxetine for Binge Eating Disorder

NCT02528409
COMPLETED NA

Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology

NCT02659787
COMPLETED NA

Thirty Million Words- Well Baby Initiative

NCT02812017
COMPLETED NA

His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy

NCT02700425
COMPLETED Phase 4

Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

NCT02754518
COMPLETED Phase 4

Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery

NCT02635542
← Previous Page 8 of 16 Next →

Phase Distribution

PhaseTrial count
Phase 1 137
Phase 2 156
Phase 3 14
Phase 4 53

Therapeutic Areas

Prostate Cancer 11
Head and Neck Cancer 8
Multiple Myeloma 6
Breast Cancer 6
COVID-19 5
Type 2 Diabetes 4
Kidney Stone 4
Surgery 4
Diabetes Mellitus, Type 1 4
Colorectal Cancer 4

What is open in the University of Chicago pipeline

158 recruiting of 796 indexed (20% open); 451 completed (57%).

Phase mix: 67 late (III/IV) vs 293 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (11 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Chicago: open-pipeline peers nationwide

Peers matched on 796 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 02004006008001,000 14%16%18%20%22% Total trials Recruiting share University of ChicagoDana-Farber Cancer InstituteUniversity of California, San DiegoUniversity of UtahUniversity of Texas Southwestern Medical CenterAcera SurgicalAlign TechnologyAltruBioAlvernia University
University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Chicago sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 796 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this University of Chicago page

796 registered trials is a research-attention snapshot, not an endorsement of University of Chicago or any single study.

  • 158 of University of Chicago's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition University of Chicago studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Chicago pipeline card: 796 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.